Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.638 USD | +1.97% | -1.37% | -5.17% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.17% | 18.34M | |
+38.73% | 723B | |
+33.98% | 595B | |
-3.05% | 369B | |
+20.71% | 332B | |
+2.76% | 282B | |
+17.36% | 244B | |
+9.49% | 208B | |
-4.66% | 205B | |
+0.49% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-15-2020 11